Drugs / eniluracil
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00827580 | Jan → Sep 2009 | breast cancer, colon carcinoma | West Virginia University | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00005050 | Aug 1999 → Jun 2001 | colorectal cancer | NYU Langone Health | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01231802 | Apr 2011 → Aug 2012 | breast cancer | Adherex Technologies, Inc. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00003873 | Apr 1999 → Jul 2007 | colon adenocarcinoma, rectum adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00004195 Comparator | Sep 1998 → Oct 1999 | colorectal cancer | University of Alabama at Birmingham | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | eniluracil | “Patients receive oral eniluracil and oral fluorouracil twice daily on days 1-21.” NCT00005050 ↗ |
| Action | Inhibit | “Evaluate the ability of eniluracil to inactivate DPD in the tumor, PBMCs, and normal tissue” NCT00004195 ↗ |
| Route | Oral | “eniluracil/fluorouracil orally twice a day for 28 days” NCT00003873 ↗ |